Relationship Between TNF-α and the Risk of Cerebral Palsy: A Systematic Review and Meta-Analysis

Baotian Wang*, Fan Wang, De Wu, Xiaoyan Xu, Li Yang, Jing Zhu, Jingjing Yuan and Jiulai Tang

Department of Pediatrics, First Affiliated Hospital of Anhui Medical University, Hefei, China

Objective: We performed a meta-analysis to investigate the relationship between blood tumor necrosis factor-alpha (TNF-α) levels and the risk of cerebral palsy (CP) in children.

Methods: PubMed, Web of Science, Cochrane Library and Ovid databases were searched from the date of database inception to 26 April 2022. Data were extracted and pooled from observational studies related to TNF-α and the risk of CP in children. Quality was assessed using the Newcastle-Ottawa Scale. We used the inverse variance method with a random-effects model to estimate the odds ratios with 95% confidence intervals (CIs), and stratified analyses and sensitivity analysis were utilized to analyse heterogeneity.

Results: Nine studies with 1,117 cases and 3,563 controls were included in our meta-analysis. The quality of the literature was good, and no publication bias was noted. According to the random-effects model, blood TNF-α levels were associated with the risk of CP (OR 1.82; 95% CI, 1.25–2.66) in a heterogeneous set of studies ($I^2 = 81.2\%$, $p = 0.000$).

Conclusion: Our findings indicate that elevated TNF-α levels in the blood are associated with an increased risk of CP. The association of TNF-α with CP requires further investigation.

Keywords: cerebral palsy, TNF-α - tumor necrosis factor alpha, pathogenesis, meta-analysis, systematic review

INTRODUCTION

Cerebral palsy (CP) is a group of permanent movement and postural disorders that are attributed to non-progressive disturbances in the developing fetal or infant brain (1). CP is the most common form of chronic motor disability in childhood, and the prevalence is 2.11 cases per 1,000 live births (2). A systematic review estimated that among children with CP, “1 in 2 had an intellectual disability; 1 in 4 had epilepsy; 1 in 4 could not talk; 1 in 4 had a behavior disorder; 1 in 10 were blind and 1 in 25 were deaf” (2). Moreover, despite advancements in medical technology in recent years, the incidence of CP has not significantly declined (3). Currently, inflammation, genetic factors and prematurity have been identified as the strongest risk factors for CP; however, in most cases, the etiology of CP remains poorly understood (4). Additionally, because the specific details of the events that lead to CP are often unknown, we cannot derive a causal relation to later neurological dysfunction in humans (4).
Tumor necrosis factor-alpha (TNF-α) is a cytokine that is mainly produced by astrocytes, microglia, blood-borne macrophages, and vascular endothelial cells in the central nervous system and plays important roles in immune modulation, the inflammatory response, cell proliferation and apoptosis. TNF-α directly induces the aggregation of multinuclear leukocytes in an injured area and activate the release of inflammatory mediators, which can be further enhanced by inducing the synthesis of inducible adhesion factors, interleukin (IL)-6, IL-2, and IL-8. Activated microglia can induce blood-brain barrier dysfunction by releasing TNF-α, which participates in the development of cerebral oedema (5). Evidence has shown that repeated increases of the concentration of TNF-α in blood contribute to CP (5–12), whereas other studies, including a meta-analysis (13), reported that there was no statistically significant correlation (13–16). It is hard to define whether the elevation of TNF-α is responsible for the CP or if both processes occur in parallel. Considering these conflicting results, we performed a meta-analysis of published observational studies to investigate whether TNF-α is associated with CP in children. Evidence of a relationship between TNF-α and CP could help illuminate the pathogenesis of this disorder.

METHODS

Literature Search and Selection Criteria

This meta-analysis adhered to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. PubMed, Web of Science, Cochrane Library and Ovid databases were searched systematically from the date of database inception to 26 April 2022. The following keywords were used in our search strategy: (“cerebral palsy”) and (“tumor necrosis factor-alpha” or “TNF-α” or “TNF-a” or “TNF-alpha” or “TNF antagonists” or “TNF inhibitors” or “TNF blockers” or “tumor necrosis factor antagonists” or “tumor necrosis factor inhibitors” or “tumor necrosis factor blockers”). In addition, manual retrieval of references of relevant original articles was performed by two reviewers (BW and FW) to avoid missing additional pertinent studies. We restricted the searches to human studies, and only articles published in English were considered.

Two authors (BW and FW) independently conducted the original search, removed duplicate articles, examined the titles and abstracts of all initially identified studies and performed a full-text evaluation of the selected articles. Any discrepancies between the two authors were resolved through discussion with the senior fellow (DW). The studies were included in the analysis if they satisfied the following criteria: (1) the study described the relationship between TNF-α and CP risk in children; (2) the sample of TNF-α were obtained from blood; (3) the article was published in English; (4) the study was an observational study; and (5) the study provided sufficient data, including odds ratios (ORs) with 95% confidence intervals (CIs). Reviews, meta-analyses, case reports, letters, editorials, animal studies, conference abstracts, simple commentaries and studies without accessible data after contacting the corresponding author were excluded.

Data Extraction and Quality Evaluation

The following data were independently extracted from each report by two reviewers (IZ and XX): the first author, year of publication, sample size, number of CP cases, definition of and diagnostic criteria for CP, participants’ age range, origin of the studied population, study duration, study design, gestational age, method of obtaining blood samples, OR for the association between CP and TNF-α and the associated 95% CI and confounders used for model adjustment.

The Newcastle-Ottawa Scale (NOS) (17) was used by two authors (LY and JY) to assess the methodological quality of each study included in the current meta-analysis. The NOS assigns a maximum of nine points to each study. We considered NOS scores of <5 stars, five to seven stars, and more than seven stars as indicators of low, medium, and high quality, respectively. Any discrepancies between the two authors were resolved through discussion with the senior fellow (JT).

Statistical Analysis

The original studies included ORs and 95% CIs estimating the relationship between TNF-α and the risk of CP in children. We used the random-effects model to calculate both the Q and I² statistics as indicators of heterogeneity. We performed subgroup analyses to identify the sources of heterogeneity among the studies. Between-subgroup heterogeneity was assessed using the fixed-effects model. The heterogeneity was considered to be high if the I² value was >50% and the p-value was <0.1. The value of the I² statistic was used to select the appropriate pooling method: fixed-effects models were used for I² < 50% and random-effects models were applied for I² > 50%. Sensitivity analyses were conducted by excluding each study one at a time to examine whether the overall effect estimate changed. Publication bias was assessed using Egger’s (18) and Begg’s tests (19). A trim-and-fill method was used to further assess the possible effect of publication bias on our meta-analysis (20). We used Stata software v15.1 (StataCorp, College Station, TX, USA) to perform the statistical tests, and p-values < 0.05 were considered statistically significant.

RESULTS

Literature Search

A total of 1,670 articles were retrieved from the databases: 109 articles from PubMed, 1,307 articles from Ovid, 20 articles from the Cochrane Library, 230 articles from Web of Science and 4 additional studies from the related references. After screening the titles and abstracts and excluding duplicates, 22 remaining records seemed to be relevant to this study. After reviewing the full-text articles, nine articles (5–11, 14, 15) were included in this meta-analysis. The flowchart for the search and selection results is shown in Figure 1.

Characteristics and Quality of the Included Studies

A summary of the study designs and main characteristics of the included studies are shown in Table 1. In total 1,117 cases and 3,563 controls were eligible and included in this study; the sample
size ranged from 74 participants (6) to 1,741 participants (15). All included studies were observational in nature, including three cohort studies (6, 7, 10), four case-control studies (5, 8, 9, 14) and one randomized controlled trial (11, 13). Four studies were conducted in the United States (8, 10, 11, 14), two studies were conducted in Europe (6, 7), one study was conducted in Australia, (15) and the others were conducted in China (5, 9). Of the five studies conducted at the beginning of the neonatal period before the diagnosis of CP, two collected blood samples from cord blood (6, 14) and three from venous blood (8, 10, 11), and all four infant studies collected venous blood samples (5, 7, 9, 15). The methods used to assess TNF-α differed among the studies, two
studies used Enzyme-linked Immunoassay (ELISA) (5, 14), three studies used SNP analysis (7, 9, 15) and four used cytometry techniques, including Cytometric Bead Array (CBA) (6), Meso Scale Discovery (MSD) electrochemiluminescence system (8, 10), Multiplex Luminox Assay (11). The total NOS scores of the nine included studies ranged from 6 to 9. The ORs with 95% CIs and the NOS quality assessment score for the eight included studies are shown in Table 1.

**Meta-Analysis and Subgroup Analyses**

The meta-analysis was performed with a random-effects model, and the pooled OR suggested a significant positive relationship between blood TNF-α levels and the risk of CP in children (pooled crude OR 1.82, 95% CI: 1.25–2.66, z = 3.11, p = 0.002) with high heterogeneity among the studies (I² = 81.2%, p = 0.000) (Figure 2). Nine studies evaluated the relationship between TNF-α and the risk of CP in children (5–11, 14, 15), and two reported no significant association (14, 15).

To determine any significant differences in outcomes among the subgroups, we conducted stratified analyses based on a few key study characteristics and clinical factors. The results of all the main and subgroup meta-analyses are shown in Table 2 and Supplementary Figures S1–S5. The relationship between TNF-α and CP risk was not substantially different among any of the subgroups. When stratified by age, the pooled estimate from the included studies revealed a significant positive relationship between blood TNF-α levels and the risk of CP in children (Table 2, Supplementary Figure S2). The definition of CP differed substantially among the included studies, but a significant positive relationship between blood TNF-α risk and the risk of CP in children was still identified (Table 2, Supplementary Figure S5). Six studies (5, 7–9, 14, 15) provided adequate information about the definition of and diagnostic criteria for CP. Some studies confirmed the diagnosis by performing examinations, whereas others did not. Cord blood studies, TNF-α polymorphism studies and studies performed in Western countries did not yield a significant pooled OR. However, a significant relationship was found in venous blood studies, TNF-α studies and studies performed in Eastern countries. This finding indicates that elevated levels of TNF-α in the venous blood are associated with an increased risk of CP in children (Table 2). The age of the included children, the form of TNF-α, the definition of CP, and the ethnicity of the population could affect the relationship between the level of TNF-α in the blood and the risk of CP in children.

**Sensitivity Analysis**

To confirm the robustness of the meta-analysis, a leave-one-out sensitivity analysis was conducted by recalculating the pooled OR after the exclusion of each study. The heterogeneity among studies changed to 28.8 after eliminating the study by O’Callaghan et al. (15) (OR 1.75; 95% CI, 1.48–2.06) (Supplementary Figure S6). The results show that the corresponding pooled OR was not substantially altered after the exclusion of any single study from the analysis (range of summary estimates: 0.22–0.98), indicating that the results of this meta-analysis are relatively stable and reliable (Figure 3).

**Publication Bias**

Egger’s and Begg’s tests were used to evaluate funnel plot asymmetry and publication bias. Although no asymmetry was observed in Begg’s funnel plot (P = 0.92), findings from Egger’s test (P = 0.04) rejected our null hypothesis about publication bias. Therefore, we performed the trim-and-fill method to recalculate our pooled risk estimate, and the missing results from four studies were imputed, producing a symmetrical funnel plot (Figures 4, 5). The pooled results did not support obvious publication bias (P = 0.208).

**DISCUSSION**

Our meta-analysis clearly suggests that TNF-α levels in the venous blood are significantly positively related to the risk of CP in children, and the results remained stable in the sensitivity analyses.

According to the existing definition, CP describes a group of movement and postural disorders that limit activity and are attributable to non-progressive disturbances in the developing fetal or neonatal brain. It is difficult to explain the relationship between TNF-α and CP. Does CP cause an increase in blood TNF-α levels? Does an increase in blood TNF-α levels cause CP? Alternatively, does an interaction occur between the two factors? Four studies (6, 8, 10, 11) found elevated levels of blood TNF-α in neonates, three studies (5, 7, 9) found elevated levels in infants, and no significant difference was noted between the two groups. According to the existing definition of CP, an increase in TNF-α in the neonatal period is a risk factor for CP. However, it is difficult to explain the increase in TNF-α in the blood of infants with CP. It is important to emphasize that brain development after an inflammation related injury is not a static event, but a complex and dynamic process, in which several cellular and molecular cascades are involved, throughout lifetime (12). To determine the association between TNF-α and CP, it is crucial to know the mechanism underlying brain injury induced by TNF-α. A relationship between TNF-α and CP in children has long been hypothesized. Because these molecules can cross the blood-brain barrier (BBB), the peripheral levels of these molecules may also reflect their levels in the brain (12). Based on the involvement of tertiary damage mechanisms (4) and a multi hit model (21, 22) brain injury processes can persist for many months or years. Multiple hits and tertiary damage mechanisms implicated in the pathogenesis of this condition include microglial activation and disturbances of apoptosis, resulting in the arrest of oligodendrocyte maturation and impaired neurogenesis, axonal growth, and synaptogenesis (21). Repeated or long-term chronic stimulation can lead to microglial aggregation and continuous activation and the release of many pro-inflammatory factors, which can generate a “waterfall” effect by activating other microglial cells and amplifying the inflammatory cascade reaction. Thus, a vicious cycle resulting in
### TABLE 1 | Characteristics of the included studies.

| Author     | Publication year | Country    | Study design            | Study period                      | Total participants | CP cases | Patients age                  | Gestational age | Test | Methods | Primary outcome | NOS score |
|------------|------------------|------------|-------------------------|-----------------------------------|--------------------|----------|------------------------------|-----------------|------|----------|-----------------|-----------|
| Wu         | 2015             | China      | Case-control            | Yes Dec 2012–Aug 2013             | 82                 | 54       | 1 y–12 y                      | NA              | ELISA| Venous blood | OR = 1.605 (CI 1.302–1.979) | 6         |
| Hansen     | 2008             | Sweden     | Cohort study           | No Feb 2001–Feb 2003              | 74                 | 5        | 24-months corrected age      | GA < 32w        | CBA  | Cord blood | OR = 3.6 (CI 1.002–12.8) | 9         |
| Vidak      | 2012             | Croatia    | Retrospective study    | Yes NA                            | 144                | 60       | 5 y                          | GA < 32w        | SNP  | Venous blood | OR = 3.286 (CI 1.067–10.116) | 8         |
| Yanni      | 2017             | USA        | Cohort study           | No 2002–2004                      | 763                | 87       | 24-months corrected age      | GA < 28w        | MSD  | Venous blood | OR = 3.1 (CI 1.2–7.9) | 9         |
| Hou        | 2016             | China      | Case-control            | Yes 2012–2014                     | 219                | 105      | mean age = 24 months         | GA > 37w        | SNP ,ELISA | Venous blood | OR = 2.75 (CI 1.23–6.13) | 9         |
| Varner     | 2015             | USA        | Randomized controlled trail | Yes Dec 1997–May 2004             | 609                | 102      | 2 y                          | 24 ≤ GA < 32    | ELISA| Cord blood | OR = 1.05 (CI 0.50–2.21) | 9         |
| Kuban      | 2014             | USA        | Case-control            | Yes 2002–2004                     | 939                | 105      | 2 y                          | GA < 28 w       | MSD  | Venous blood | OR = 3.5 (CI 1.4–8.6) | 6         |
| O’Callaghan | 2013            | Australia  | Case-control            | Yes Jul 2006–Mar 2010             | 1,741              | 587      | 5 y–18 y                      | Average gestational age = 35.3w | SNP  | Venous blood | OR = 0.79 (CI 0.62–1.0) | 7         |
| Pappas     | 2020             | USA        | Randomized controlled trail | No Jul 2001–Aug 2010             | 109                | 12       | 0 y–7 y                       | NA             | Luminex Assay | Venous blood | OR = 1.66 (CI 1.10–2.51) | 6         |
FIGURE 2 | Forest plot of the association between the blood levels of TNF-α and cerebral palsy based on the OR. Weights are obtained from random effects analysis. CI, confidence interval.

TABLE 2 | Pooled results of the association between blood TNF-α levels and CP.

| Variables                      | Studies (n) | OR (95% CI)    | $I^2$ (P-values for heterogeneity) | $P$-values* |
|-------------------------------|-------------|----------------|-----------------------------------|-------------|
| Total                         | 9           | 1.82 (1.25–2.66)| 81.2% (p = 0.000)                 |             |
| Samples                       |             |                |                                   |             |
| Venous blood                  | 7           | 1.25 (1.10–1.41)| 84.9% (p = 0.000)                 | 0.671       |
| Cord blood                    | 2           | 1.44 (0.76–2.74)| 62.7% (p = 0.102)                 |             |
| Patients age                  |             |                |                                   |             |
| Neonate                       | 5           | 1.87 (1.38–2.54)| 39.2% (p = 0.160)                 | 0.005       |
| Infant                        | 4           | 1.16 (1.02–1.33)| 89.4% (p = 0.000)                 |             |
| Form of TNF-α                 |             |                |                                   |             |
| TNF-α                         | 6           | 1.68 (1.42–2.00)| 30.8% (p = 0.205)                 | 0.000       |
| TNF-α polymorphisms           | 3           | 0.93 (0.78–1.11)| 84.4% (p = 0.002)                 |             |
| Country                       |             |                |                                   |             |
| East country                  | 2           | 1.66 (1.36–2.03)| 38.2% (p = 0.203)                 | 0.001       |
| West country                  | 7           | 1.07 (0.91–1.24)| 79.5% (p = 0.000)                 |             |
| Definition and diagnosis      |             |                |                                   |             |
| Yes                           | 6           | 1.19 (1.04–1.35)| 85.3% (p = 0.000)                 | 0.012       |
| No                            | 3           | 1.94 (1.35–2.78)| 16.8% (p = 0.301)                 |             |

*Overall test for heterogeneity between subgroups was performed using the inverse variance method.
Wang et al. Relationship Between TNF-α and CP

FIGURE 3 | Sensitivity analysis for individual studies on the summary effect.

brain injury occurs. TNF-α is one of the most important pro-inflammatory cytokines, and it plays pivotal roles in systemic inflammation, apoptosis and necrosis (Figure 6 (23)). TNF-α inhibits the differentiation of oligodendrocyte progenitor cells, lead to white matter injury (24), modulate synaptic connectivity and facilitates glutamate-dependent neuron death, which may have a damaging effect on gray matter structures (5) and contribute to brain injury. CP may be caused by undetectable progressive brain injury, and TNF-α may be involved.

Another early meta-analysis did not detect an association between the TNF-α gene rs1800629 polymorphisms and CP (13), which was different from our finding that elevated blood TNF-α levels are related to an increased risk of CP. The relationship between TNF-α gene polymorphisms and the risk of CP in children remains controversial. Vidak et al. (7) and Hou et al. (9) believed that TNF-α gene polymorphisms were significantly associated with CP; however, Wu et al. (13) and O’Callaghan et al. (15) reported the opposite result. Our meta-analysis suggested that the age of the included children, the form of TNF-α, the definition of CP, and the ethnicity of the population could affect the relationship between blood TNF-α levels and the risk of CP in children. Although our results indicates high heterogeneity among the studies, when we omitted the study by O’Callaghan et al. (15) from the analysis, the heterogeneity index decreased to a low level (Supplementary Figure S6). The changes did not alter the statistical or clinical significance of the original findings. Therefore, we suggest that the results are robust. Because the development of CP involves inflammation, these findings may affect the long-term health of children. It is important to emphasize that brain development after an inflammation related injury is not a static event, but a complex and dynamic process, in which several cellular and molecular cascades are involved, throughout lifetime (12).

However, some studies have reported no relationship between the level of TNF-α in cord blood and the risk of CP in children (14). What is the mechanism by which TNF-α levels are not be elevated in the cord blood immediately after birth but become elevated in the venous blood after birth? The mechanism underlying the elevated plasma levels of TNF-α in children with CP may partly be related to an increase in the secretion of TNF-α by peripheral blood mono-nuclear cells (24). Therefore, it is possible that the level of TNF-α in fetal blood could be elevated, but this elevated level is not detectable in cord blood at the time of sampling (25).
A recent paper by Pham et al. (26) expressed concern that most published genetic studies of CP poorly or inadequately defined their inclusion criteria for CP. According to the Pham et al. study (26), limited compliance with international consensus guidelines regarding the phenotypic definition of CP and mediocre reporting of CP case ascertainment criteria hinders the comparison of results among genetic studies of CP (including meta-analyses), thereby limiting the quality, interpretability, and generalizability of study findings (26). Our results also suggest that the definition of and diagnostic criteria for CP could affect the relationship between blood TNF-α levels and the risk of CP in children. A subgroup analysis of studies stratified based on description of these aspects found that there were differences in the results ($P = 0.01$); however, the main finding that blood TNF-α levels were associated with the risk of CP remained the same (Table 2, Supplementary Figure S5).

The results of our meta-analysis indicate that the level of TNF-α in children is significantly positively related to the risk of CP, regardless of age (Supplementary Figure S2). Moreover, the present study suggests that the severity of CP is correlated with the TNF-α level in the blood (5). Based on these findings, future studies should focus on elucidating the mechanisms underlying TNF-α-induced brain injury, which may provide additional information about the relationship between blood TNF-α levels and the risk of CP in children.

**Figure 6** A model of TNF-α signaling in inflammation, apoptosis and necrosis (23).

To the best of our knowledge, our study is the first meta-analysis to provide evidence that blood TNF-α levels are
significantly positively related to the risk of CP in children. However, several limitations should be taken into account. First, the studies used different time-points in their research, impairing the comparison of their findings. Second, we only included studies published in English. Third, the involved studies were all observational in design, it is also difficult to obtain homogenous groups in observational studies and the number of included studies was small. Finally, the bias inherent in observational studies is not eliminated in a quantitative synthesis. In fact, some preterm studies already performed on a subgroup. This already biases our outcome as you know preterm birth is a risk factor for higher inflammation and diagnosis for CP.

CONCLUSIONS

In conclusion, our pooled analyses provide evidence that elevated blood TNF-α levels are related to an increased risk of CP. However, the causal pathway underlying this relationship remains to be elucidated. Hence, future studies that explain the effects of TNF-α on CP are needed.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

BW: conceptualization, methodology, software, formal analysis, visualization, and writing—original draft preparation. FW, XX, and JZ: data curation. DW: methodology, formal analysis, and supervision. LY: software, formal analysis, and visualization. JY: software and visualization. JT: project administration and writing—reviewing and editing. All authors have read and approved the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2022.929280/full#supplementary-material
REFERENCES

1. Novak I, Morgan C, Adde L, Blackman J, Boyd RN, Hernandez J, et al. Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment. JAMA Pediatr. (2017) 171:897–907. doi: 10.1001/jamapediatrics.2017.1689

2. Shepherd E, Salam RA, Middleton P, Han S, Makrides M, McIntyre S, et al. Neonatal interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. (2018) 6:CD012409. doi: 10.1002/14651858.CD012409.pub2

3. Nguyen AT, Bahry AM, Shen KQ, Armstrong EA, Yager JY. Consumption of broccoli sprouts during late gestation and lactation confers protection against developmental delay induced by maternal inflammation. Behav Brain Res. (2016) 307:239–49. doi: 10.1016/j.bbr.2016.03.017

4. Fleiss B, Grossens P. Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? Lancet Neurol. (2012) 11:556–66. doi: 10.1016/S1474-4422(12)70058-3

5. Wu J, Li X. Plasma tumor necrosis factor-alpha (TNF-α) subnormal development in very preterm infants. Med Monit. (2015) 1:872–7. doi: 10.12659/MSM.895400

6. Hansen-Pupp I, Hallin AL, Hellström-Westas L, Cilio C, Berg AN, Stjernqvist K, et al. Inflammation at birth is associated with subnormal development in very preterm infants. Pediatr Res. (2008) 64:183–8. doi: 10.1203/PDR.0b013e318176144d

7. Vidak HK, Ivković TC, Jokić M, Spaventi R, Kapitanović S. The association between proinflammatory cytokine polymorphisms and cerebral palsy in very preterm infants. Cytokine. (2012) 58:57–64. doi: 10.1016/j.cytjo.2011.12.018

8. Kuban KCK, O’Shea TM, Allred EN, Paneth N, Hirtz D, Fichorova RN, et al. Systemic inflammation and cerebral palsy risk in extremely preterm infants. J Child Neurol. (2014) 29:1692–8. doi: 10.1177/0883073813513333

9. Hou R, Ren X, Wang J, Guan X. TNF-α and MTHFR polymorphisms associated with cerebral palsy in Chinese infants. Mol Neurobiol. (2016) 53:1–6. doi: 10.1007/s12035-015-9566-7

10. Yanni D, Korzeniewski SJ, Allred EN, Fichorova RN, O’Shea TM, Kuban K, et al. Both antenatal and postnatal inflammation contribute information about the risk of brain damage in extremely preterm newborns. Pediatr Res. (2017) 82:691–6. doi: 10.1038/pr.2017.128

11. Pappas A, Shankaran S, McDonald SA, Carlo WA, Laptook AR, Tyson JE, et al. Blood biomarkers and 6-7-year childhood outcomes following neonatal encephalopathy. Am J Perinatol. (2020). doi: 10.1055/s-0040-1717072. [Epub ahead of print]

12. Magalhães RC, Moreira JM, Laurao AO, da Silva AAS, Teixeira AL, Silva ACS. Inflammatory biomarkers in cerebral palsy: a systematic review. Res Dev Disabil. (2019) 95:103508. doi: 10.1016/j.ridd.2019.103508

13. Wu D, Zou YF, Xu YY, Feng XL, Yang L, Zhang GC, et al. The association of genetic polymorphisms with cerebral palsy: a meta-analysis. Dev Med Child Neurol. (2011) 53:217–25. doi: 10.1111/j.1469-8749.2010.03884.x

14. Varner MW, Marshall NE, Rouse DJ, Jablonski KA, Leveno KJ, Reddy UM, et al. The association of cord serum cytokines with neurodevelopmental outcomes. Am J Perinatol. (2015) 32:115–22. doi: 10.1055/s-0034-1376185

15. O’Callaghan ME, Maclellan AH, Gibson CS, McMichael GL, Haan EA, Broadhurst JL, et al. Genetic and clinical contributions to cerebral palsy: a multi-variable analysis. J Paediatr Child Health. (2013) 49:575–81. doi: 10.1111/jpc.12279

16. Zareen Z, Strickland T, Fallah L, McEneaney V, Kelly L, McDonald D, et al. Cytokine dysregulation in children with cerebral palsy. Dev Med Child Neurol. (2021) 63:407–12. doi: 10.1111/dmcn.14724

17. Wells GA, O’Connell D, Peterson J, Welch V, Tugwell P, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Available online at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm

18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629

19. Legg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. (1994) 50:1088–101. doi: 10.2307/2533446

20. Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-analyst: software for metaanalysis of binary, continuous and diagnostic data. BMC Med Res Methodol. (2009) 9:80. doi: 10.1186/1471-2288-9-80

21. Korzeniewski SJ, Romero R, Cortez J, Pappas A, Schwartz AG, Kin CJ, et al. A “multi-hit” model of neonatal white matter injury: cumulative contributions of chronic placental inflammation, acute fetal inflammation and postnatal inflammatory events. J Perinat Med. (2014) 42:731–43. doi: 10.1515/jpm-2014-0250

22. Mer O, Stavisky M, Yitshak-Sade M, Mastroia M, Keele W, Raffaelli Yehudai T, et al. Early onset preeclampsia and cerebral palsy: a double hit model. Am J Obstet Gynecol. (2016) 214:105. doi: 10.1016/j.ajog.2015.08.020

23. Chiu W, Tumor necrosis factor. Cancer Lett. (2013) 328:222–5. doi: 10.1016/j.canlet.2012.10.014

24. Lin CY, Chang YC, Wang ST, Lee TY, Lin CF, Huang CC. Altered inflammatory responses in preterm children with cerebral palsy. Ann Neurol. (2010) 68:204–12. doi: 10.1002/ana.22049

25. Yoon BH, Jun JK, Romero R, Park KH, Gomez R, Choi JH, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1β, and tumor necrosis factor-α), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol. (1997) 177:19–26. doi: 10.1016/S0002-9378(97)07432-0

26. Pham R, Mol BW, Gecc J, MacLennan AH, MacLennan SC, Corbett MA, et al. Definition and diagnosis of cerebral palsy in genetic studies: a systematic review. Dev Med Child Neurol. (2020) 62:1024–30. doi: 10.1111/dmcn.14585

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Wang, Wu, Xu, Yang, Zhu, Yuan and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.